Theta-burst rTMS in schizophrenia to ameliorate negative and cognitive symptoms : study protocol for a double-blind, sham-controlled, randomized clinical trial
© 2024. The Author(s)..
BACKGROUND: Treatment effects of conventional approaches with antipsychotics or psychosocial interventions are limited when it comes to reducing negative and cognitive symptoms in schizophrenia. While there is emerging clinical evidence that new, augmented protocols based on theta-burst stimulation can increase rTMS efficacy dramatically in depression, data on similar augmented therapies are limited in schizophrenia. The different patterns of network impairments in subjects may underlie that some but not all patients responded to given stimulation locations.
METHODS: Therefore, we propose an augmented theta-burst stimulation protocol in schizophrenia by stimulating both locations connected to negative symptoms: (1) the left dorsolateral prefrontal cortex (DLPFC), and (2) the vermis of the cerebellum. Ninety subjects with schizophrenia presenting negative symptoms and aging between 18 and 55 years will be randomized to active and sham stimulation in a 1:1 ratio. The TBS parameters we adopted follow the standard TBS protocols, with 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 100% active motor threshold. We plan to deliver 1800 stimuli to the left DLPFC and 1800 stimuli to the vermis daily in two 9.5-min blocks for 4 weeks. The primary endpoint is the change in negative symptom severity measured by the Positive and Negative Syndrome Scale (PANSS). Secondary efficacy endpoints are changes in cognitive flexibility, executive functioning, short-term memory, social cognition, and facial emotion recognition. The difference between study groups will be analyzed by a linear mixed model analysis with the difference relative to baseline in efficacy variables as the dependent variable and treatment group, visit, and treatment-by-visit interaction as independent variables. The safety outcome is the number of serious adverse events.
DISCUSSION: This is a double-blind, sham-controlled, randomized medical device study to assess the efficacy and safety of an augmented theta-burst rTMS treatment in schizophrenia. We hypothesize that social cognition and negative symptoms of patients on active therapy will improve significantly compared to patients on sham treatment.
TRIAL REGISTRATION: The study protocol is registered at "ClinicalTrials.gov" with the following ID: NCT05100888. All items from the World Health Organization Trial Registration Data Set are registered. Initial release: 10/19/2021.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Trials - 25(2024), 1 vom: 17. Apr., Seite 269 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Csukly, Gábor [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical Trial Protocol |
|---|
| Anmerkungen: |
Date Completed 19.04.2024 Date Revised 25.04.2024 published: Electronic ClinicalTrials.gov: NCT05100888 Citation Status MEDLINE |
|---|
| doi: |
10.1186/s13063-024-08106-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371217369 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371217369 | ||
| 003 | DE-627 | ||
| 005 | 20240425235137.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240418s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13063-024-08106-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM371217369 | ||
| 035 | |a (NLM)38632647 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Csukly, Gábor |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Theta-burst rTMS in schizophrenia to ameliorate negative and cognitive symptoms |b study protocol for a double-blind, sham-controlled, randomized clinical trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.04.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT05100888 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a BACKGROUND: Treatment effects of conventional approaches with antipsychotics or psychosocial interventions are limited when it comes to reducing negative and cognitive symptoms in schizophrenia. While there is emerging clinical evidence that new, augmented protocols based on theta-burst stimulation can increase rTMS efficacy dramatically in depression, data on similar augmented therapies are limited in schizophrenia. The different patterns of network impairments in subjects may underlie that some but not all patients responded to given stimulation locations | ||
| 520 | |a METHODS: Therefore, we propose an augmented theta-burst stimulation protocol in schizophrenia by stimulating both locations connected to negative symptoms: (1) the left dorsolateral prefrontal cortex (DLPFC), and (2) the vermis of the cerebellum. Ninety subjects with schizophrenia presenting negative symptoms and aging between 18 and 55 years will be randomized to active and sham stimulation in a 1:1 ratio. The TBS parameters we adopted follow the standard TBS protocols, with 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 100% active motor threshold. We plan to deliver 1800 stimuli to the left DLPFC and 1800 stimuli to the vermis daily in two 9.5-min blocks for 4 weeks. The primary endpoint is the change in negative symptom severity measured by the Positive and Negative Syndrome Scale (PANSS). Secondary efficacy endpoints are changes in cognitive flexibility, executive functioning, short-term memory, social cognition, and facial emotion recognition. The difference between study groups will be analyzed by a linear mixed model analysis with the difference relative to baseline in efficacy variables as the dependent variable and treatment group, visit, and treatment-by-visit interaction as independent variables. The safety outcome is the number of serious adverse events | ||
| 520 | |a DISCUSSION: This is a double-blind, sham-controlled, randomized medical device study to assess the efficacy and safety of an augmented theta-burst rTMS treatment in schizophrenia. We hypothesize that social cognition and negative symptoms of patients on active therapy will improve significantly compared to patients on sham treatment | ||
| 520 | |a TRIAL REGISTRATION: The study protocol is registered at "ClinicalTrials.gov" with the following ID: NCT05100888. All items from the World Health Organization Trial Registration Data Set are registered. Initial release: 10/19/2021 | ||
| 650 | 4 | |a Clinical Trial Protocol | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cognitive symptoms | |
| 650 | 4 | |a Negative symptoms | |
| 650 | 4 | |a Schizophrenia | |
| 650 | 4 | |a Theta-burst | |
| 650 | 4 | |a Transcranial magnetic stimulation | |
| 700 | 1 | |a Orbán-Szigeti, Boglárka |e verfasserin |4 aut | |
| 700 | 1 | |a Suri, Karolin |e verfasserin |4 aut | |
| 700 | 1 | |a Zsigmond, Réka |e verfasserin |4 aut | |
| 700 | 1 | |a Hermán, Levente |e verfasserin |4 aut | |
| 700 | 1 | |a Simon, Viktória |e verfasserin |4 aut | |
| 700 | 1 | |a Kabaji, Anita |e verfasserin |4 aut | |
| 700 | 1 | |a Bata, Barnabás |e verfasserin |4 aut | |
| 700 | 1 | |a Hársfalvi, Péter |e verfasserin |4 aut | |
| 700 | 1 | |a Vass, Edit |e verfasserin |4 aut | |
| 700 | 1 | |a Csibri, Éva |e verfasserin |4 aut | |
| 700 | 1 | |a Farkas, Kinga |e verfasserin |4 aut | |
| 700 | 1 | |a Réthelyi, János |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Trials |d 2006 |g 25(2024), 1 vom: 17. Apr., Seite 269 |w (DE-627)NLM161320430 |x 1745-6215 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2024 |g number:1 |g day:17 |g month:04 |g pages:269 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13063-024-08106-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2024 |e 1 |b 17 |c 04 |h 269 | ||